skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Percutaneous Lung Thermal Ablation of Non-surgical Clinical N0 Non-small Cell Lung Cancer: Results of Eight Years’ Experience in 87 Patients from Two Centers

Journal Article · · Cardiovascular and Interventional Radiology
 [1];  [2];  [3];  [4];  [5]
  1. Institut Bergonié, Comprehensive Cancer Centre, Department of Interventional Radiology (France)
  2. Institut Bergonié, Comprehensive Cancer Center, Radiation Oncology Department (France)
  3. Institut Gustave-Roussy, Unit of Biostatistics and Epidemiology (France)
  4. Institut Gustave-Roussy, Department of Interventional Radiology (France)
  5. Institut Bergonié, Comprehensive Cancer Center, Department of medical oncology (France)

PurposeTo evaluate the survival outcomes of percutaneous thermal ablation (RFA + microwaves) for patients presenting N0 non-small-cell lung cancer (NSCLC) ineligible for surgery.Materials and MethodsEighty-seven patients from two comprehensive cancer centers were included. Eighty-two patients were treated with RFA electrodes and five with microwave antenna. Overall survival (OS) and disease-free survival (DFS) were estimated and predictive factors of local tumor progression, OS and DFS identified and compared by univariate and multivariate analysesResultsMedian follow-up was 30.5 months (interquartile range 16.7–51) and tumor size was 21 mm (range 10–54 mm). Treatment was incomplete for 14 patients with a local tumor progression of 11.5, 18.3, and 21.1 % at 1, 2, and 3 years, respectively. Two patients presented with neurological (grade III or IV) complications, and one died of respiratory and multivisceral failure as a result of the procedure at 29 days. In univariate analysis, increasing tumor size (P = 0.003) was the only predictive factor related to risk of local tumor progression. 5-year OS and DFS were 58.1 and 27.9 %, respectively. Sex (P = 0.044), pathology (P = 0.032), and tumor size >2 cm (P = 0.046) were prognostic factors for DFS. In multivariate analysis, pathology (P = 0.033) and tumor size >2 cm (P = 0.032) were independent prognostic factors for DFS.ConclusionsOversized and overlapping ablation of N0 NSCLC was well tolerated, effective, with few local tumor progressions, even over long-term follow-up. Increasing tumor size was the main prognostic factor linked to OS, DFS, and local tumor progression.

OSTI ID:
22470090
Journal Information:
Cardiovascular and Interventional Radiology, Vol. 38, Issue 1; Conference: IROS 2015: Interventional Radiological Olbert Symposium, Berlin (Germany), 15-17 Jan 2015; Other Information: Copyright (c) 2015 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); http://www.springer-ny.com; Country of input: International Atomic Energy Agency (IAEA); ISSN 0174-1551
Country of Publication:
United States
Language:
English

Similar Records

An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone
Journal Article · Mon Aug 01 00:00:00 EDT 2005 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22470090

Definitive Primary Therapy in Patients Presenting With Oligometastatic Non-Small Cell Lung Cancer
Journal Article · Tue Jul 15 00:00:00 EDT 2014 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22470090

Prognostic Impact of Radiation Therapy to the Primary Tumor in Patients With Non-small Cell Lung Cancer and Oligometastasis at Diagnosis
Journal Article · Sat Sep 01 00:00:00 EDT 2012 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22470090